Kimberly Gentile is VP at Biohaven Pharmaceutical Holding Co Ltd. (BHVN). They have made 12 open-market trades across 1 company since 2017, most recently 2026-01-05.
CIK 0001704186
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 12 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BHVN | 101,513 | $1.1M |
Shares reported on the most recent Form 4, priced at the 2026-01-07 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BHVN | SELL | 2020-10-08 | 2020-10-09 | $76.35 | $3.6M | -1.4% | +3.1% | +9.5% |
| BHVN | SELL · 10b5-1 | 2020-06-17 | 2020-06-18 | $70.20 | $28K | -2.5% | -1.9% | -16.2% |
| BHVN | SELL | 2020-06-17 | 2020-06-17 | $70.20 | $1.7M | -5.8% | -1.2% | -14.3% |
| BHVN | SELL · 10b5-1 | 2020-06-08 | 2020-06-10 | $70.05 | $42K | +13.7% | +14.4% | -3.2% |
| BHVN | SELL | 2019-11-20 | 2019-11-22 | $53.04 | $2.7M | -5.1% | -4.5% | -19.0% |
| BHVN | SELL | 2018-06-15 | 2018-06-19 | $40.02 | $1.0M | -7.0% | -14.3% | -15.6% |
| BHVN | SELL | 2018-03-01 | 2018-03-05 | $32.87 | $164K | -17.9% | -24.2% | +3.6% |
| BHVN | SELL | 2018-02-01 | 2018-02-02 | $32.37 | $109K | -6.3% | +4.1% | -12.3% |
| BHVN | SELL | 2018-02-01 | 2018-02-02 | $32.78 | $164K | -6.3% | +4.1% | -12.3% |
| BHVN | SELL | 2018-01-02 | 2018-01-03 | $27.60 | $138K | -6.6% | +12.7% | -11.8% |
| BHVN | SELL | 2017-12-01 | 2017-12-05 | $21.99 | $110K | +6.0% | +37.3% | +58.1% |
| BHVN | SELL | 2017-12-01 | 2017-12-05 | $22.42 | $63K | +6.0% | +37.3% | +58.1% |
| BHVN | SELL | 2017-11-01 | 2017-11-02 | $29.13 | $104K | -15.5% | -26.6% | +19.7% |
| BHVN | SELL | 2017-11-01 | 2017-11-02 | $29.28 | $146K | -15.5% | -26.6% | +19.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.